<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Preventive treatment of episodic migraine in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Preventive treatment of episodic migraine in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Preventive treatment of episodic migraine in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd J Schwedt, MD, MSCI</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ivan Garza, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jerry W Swanson, MD, MHPE</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Migraine is a common disorder with one-year prevalence estimates of approximately 17 percent in females and 6 percent in males. (See  <a class="medical medical_review" href="/z/d/html/3348.html" rel="external">"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults", section on 'Epidemiology'</a>.)</p><p>The preventive treatment of episodic migraine headache in adults is reviewed here. The clinical features and management of chronic migraine (defined as ≥15 headache days per month) are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3337.html" rel="external">"Chronic migraine"</a>.)</p><p>Other aspects of migraine are reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3347.html" rel="external">"Acute treatment of migraine in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3348.html" rel="external">"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">INDICATIONS</span><span class="headingEndMark"> — </span>Many migraine sufferers can benefit from preventive migraine treatment. Indications include the following [<a href="#rid1">1-6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Frequent or long-lasting migraine headaches</p><p class="bulletIndent1"><span class="glyph">●</span>Migraine attacks that cause significant disability or diminished quality of life despite appropriate acute treatment</p><p class="bulletIndent1"><span class="glyph">●</span>Contraindication to acute therapies</p><p class="bulletIndent1"><span class="glyph">●</span>Failure of acute therapies</p><p class="bulletIndent1"><span class="glyph">●</span>Serious adverse effects of acute therapies</p><p class="bulletIndent1"><span class="glyph">●</span>Risk of medication overuse headache</p><p class="bulletIndent1"><span class="glyph">●</span>Menstrual migraine</p><p></p><p>While there are no strict definitions for the precise frequency or duration of migraine headaches that would prompt preventive therapy, more than four headaches per month or headaches that last longer than 12 hours are generally considered reasonable thresholds.</p><p>The main goals of preventive therapy are to [<a href="#rid1">1,7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Reduce attack frequency, severity, and duration</p><p class="bulletIndent1"><span class="glyph">●</span>Improve responsiveness to treatment of acute attacks</p><p class="bulletIndent1"><span class="glyph">●</span>Improve function and reduce disability</p><p class="bulletIndent1"><span class="glyph">●</span>Prevent progression or transformation of episodic migraine to chronic migraine</p><p></p><p>Based on expert consensus, preventive migraine therapy also is indicated to reduce the risk of neurologic damage and/or impairment in the presence of uncommon migraine conditions including [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hemiplegic migraine (see  <a class="medical medical_review" href="/z/d/html/14112.html" rel="external">"Hemiplegic migraine"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Migraine with brainstem aura (see  <a class="medical medical_review" href="/z/d/html/3352.html" rel="external">"Migraine with brainstem aura"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent aura without infarction (see  <a class="medical medical_review" href="/z/d/html/3348.html" rel="external">"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults", section on 'Complications of migraine'</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Migrainous infarction (see  <a class="medical medical_review" href="/z/d/html/3344.html" rel="external">"Migraine-associated stroke: risk factors, diagnosis, and prevention", section on 'Migraine-associated ischemic stroke'</a>)</p><p></p><p>In addition, short-term preventive therapy during the perimenstrual period may be useful for female patients who have menstrual migraine that occurs on a predictable schedule. (See  <a class="medical medical_review" href="/z/d/html/5441.html" rel="external">"Estrogen-associated migraine headache, including menstrual migraine", section on 'Hormonal contraceptives for continuous prophylaxis'</a>.)</p><p class="headingAnchor" id="H111892288"><span class="h1">OUR APPROACH</span><span class="headingEndMark"> — </span>Our approach to choosing preventive treatment of migraine is outlined in the sections that follow.</p><p class="headingAnchor" id="H382445576"><span class="h2">Choosing pharmacologic therapy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>First-line agents</strong> – For most patients with episodic migraine (≤14 headache days per month) who have an indication for preventive therapy (see <a class="local">'Indications'</a> above), we suggest initial treatment with <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a>, <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a>, one of the beta blockers (<a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a> or <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a>), or <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a>.</p><p></p><p class="bulletIndent1">Approximately half of patients given any of these drugs will have a 50 percent reduction in the frequency of headache, but the doses required may lead to intolerable side effects [<a href="#rid8">8</a>]. The choice among preventive agents of similar efficacy should be individualized according to patient-specific characteristics, comorbid conditions, medication side effect profile, medication cost, and patient values and preferences [<a href="#rid9">9-11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Second-line agents</strong> – We suggest the use of second-line agents for the prevention of episodic migraine for patients with a contraindication to or inadequate response (after at least eight weeks at a therapeutic dose) of two or more first-line drugs. These include other antihypertensives, the calcitonin gene-related peptide (CGRP) antagonists, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, and <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>.</p><p></p><p class="bulletIndent1">CGRP antagonists are reasonable options for patients with marked disability from frequent migraine who do not respond to or cannot tolerate other options [<a href="#rid12">12</a>]. They may provide earlier benefit than other preventive agents, and the formulations given by injection may also be helpful for those who have difficulty complying with preventive medications that require daily pills. However, high cost and barriers to insurance approval may limit their access.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">Valproate</a> should not be used for females of childbearing potential, because it is teratogenic and is associated with an increased risk of congenital anomalies. However, it may be considered for those utilizing effective contraception if other options are not effective or tolerated. The approach to migraine prevention during pregnancy and the postpartum period is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4797.html" rel="external">"Headache during pregnancy and postpartum", section on 'Preventive therapies'</a>.)</p><p></p><p>The presence of associated conditions and comorbid disorders can also help to guide the choice of migraine therapy:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with hypertension who are nonsmokers and ≤60 years of age, reasonable options include <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a>, <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a>, or <a class="drug drug_general" data-topicid="9997" href="/z/d/drug information/9997.html" rel="external">timolol</a> in the absence of contraindications to beta blockers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with hypertension who are smokers or are &gt;60 years of age, options include <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a> or <a class="drug drug_general" data-topicid="8869" href="/z/d/drug information/8869.html" rel="external">flunarizine</a>. We suggest not using beta blockers as initial therapy for migraine prevention in these patients because beta blockers may be associated with a higher rate of cardiovascular events compared with other antihypertensive drugs in the primary treatment of hypertension. (See  <a class="medical medical_review" href="/z/d/html/3869.html" rel="external">"Choice of drug therapy in primary (essential) hypertension"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with depression or mood disorder, reasonable options include <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a> or <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with epilepsy, reasonable options include <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> or <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with insomnia, <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a> is a reasonable option.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with obesity, <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> is a reasonable option.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with Raynaud phenomenon, reasonable options include <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a> or <a class="drug drug_general" data-topicid="8869" href="/z/d/drug information/8869.html" rel="external">flunarizine</a>.</p><p></p><p>However, comorbid disorders cannot be the sole factor in selecting therapy. A number of issues may preclude the use of specific agents or classes of medications, including contraindications, side effects, patient preferences, and cost  (<a class="graphic graphic_table graphicRef141580" href="/z/d/graphic/141580.html" rel="external">table 1</a>).</p><p>The treatment of chronic migraine (≥15 headache days per month) is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/3337.html" rel="external">"Chronic migraine", section on 'Management'</a>.)</p><p class="headingAnchor" id="H111892374"><span class="h2">Principles of preventive therapy</span><span class="headingEndMark"> — </span>Regardless of the drug chosen, some general principles may improve the success rate of preventive migraine therapy, improve treatment adherence, and reduce complications [<a href="#rid9">9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Start an oral migraine preventive medication at a low dose. Increase the dose gradually until therapeutic benefit is achieved, the maximum dose of the drug is reached, or side effects become intolerable.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Give the chosen medication an adequate trial in terms of duration and dosage. Clinical trials suggest efficacy for some agents may be first noted at four weeks but can continue to increase for three to six months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoid overuse of acute headache therapies including analgesics, triptans, and ergots.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Opioids and barbiturates should not be used for the acute or preventive treatment of migraine. Opioid use can contribute to development of chronic daily headache and can interfere with other preventive therapies. (See  <a class="medical medical_review" href="/z/d/html/3347.html" rel="external">"Acute treatment of migraine in adults", section on 'Opioids and barbiturates'</a> and  <a class="medical medical_review" href="/z/d/html/3340.html" rel="external">"Medication overuse headache: Etiology, clinical features, and diagnosis", section on 'Causal medications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Females of childbearing potential must be warned of any potential risks. Avoid <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> for this group if possible, avoid <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> during pregnancy, and choose the medication that will have the least adverse effect on the fetus. (See  <a class="medical medical_review" href="/z/d/html/4797.html" rel="external">"Headache during pregnancy and postpartum", section on 'Preventive therapies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Address patient expectations and consider patient preferences when deciding between drugs of relatively equivalent efficacy. Discuss the rationale, dosing, and likely side effects for a particular treatment. Discuss expected benefits of therapy and how long it will take to achieve them. Preventive migraine therapy requires a sustained commitment on the part of the patient and physician to achieve benefit.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Migraine may improve independent of treatment. If migraine is well controlled, slowly taper the drug if possible. Many patients experience continued relief with either a lower dose or cessation of the medication.</p><p></p><p class="headingAnchor" id="H382445541"><span class="h2">Treatment failure</span><span class="headingEndMark"> — </span>We suggest switching to a migraine prevention medication from a different class for patients who fail to improve despite an adequate trial of initial pharmacologic therapy. Clinical trials have shown that switching to another preventive agent can be effective for individuals who have failed prior migraine preventive therapies [<a href="#rid4">4,13-17</a>].</p><p class="headingAnchor" id="H1618032061"><span class="h2">Lifestyle measures</span><span class="headingEndMark"> — </span>Therapeutic lifestyle measures may be beneficial for controlling migraine, including good sleep hygiene, routine meal schedules, regular exercise, and managing migraine triggers. (See <a class="local">'Nonpharmacologic interventions'</a> below and  <a class="medical medical_review" href="/z/d/html/3348.html" rel="external">"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults", section on 'Precipitating and exacerbating factors'</a>.)</p><p>While few high-quality, placebo-controlled trials have evaluated the efficacy of these factors for migraine prevention, we recommend therapeutic lifestyle measures because they may be effective and are unlikely to cause any harm. A <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fheadaches.org%2Fwp-content%2Fuploads%2F2018%2F08%2FHEADACHE-DIARY.pdf&amp;token=r7FtEhYil7Rblm4YlaJVqa4xIqwc1nSSd568vXmUdziaKlK68o%2F5QMNmJlPbNQyHPoUgzD0Bznh5gfvWNJvNcLbt8zJIgEX3Jfg028xpx64%3D&amp;TOPIC_ID=3345" target="_blank">headache diary</a> is useful for estimating the number and severity of headaches each month and for identifying precipitating factors so that so they can be managed. The optimal management of headache trigger factors is uncertain; traditional teaching emphasizes avoidance, while newer approaches emphasize coping strategies. (See <a class="local">'Desensitizing triggers'</a> below.)</p><p class="headingAnchor" id="H182632253"><span class="h1">INTERVENTIONS</span><span class="headingEndMark"> — </span>Pharmacotherapy and lifestyle measures are the mainstay of migraine prevention.</p><p class="headingAnchor" id="H4"><span class="h2">Antihypertensives</span><span class="headingEndMark"> — </span>Data from randomized clinical trials show that beta blockers and angiotensin II receptor blockers (ARBs) are effective for migraine prevention [<a href="#rid2">2,18-20</a>]. Lower quality evidence suggests but does not establish that calcium channel blockers and angiotensin converting enzyme (ACE) inhibitors are also effective for migraine prevention. There are no clinical trial data for thiazide diuretics in migraine prevention.</p><p>Blood pressure treatment appears to reduce the overall prevalence of headache in general. This point is illustrated by the results of a meta-analysis of 94 randomized controlled trials examining four different classes of antihypertensive medications (beta blockers, ACE inhibitors, ARBs, and thiazides) that also included data on headache prevalence [<a href="#rid21">21</a>]. Patients assigned to blood pressure treatment had a significant reduction in headache prevalence compared with placebo treatment (odds ratio [OR] 0.67, 95% CI 0.61-0.74), and headache prevalence was significantly reduced in each of the four classes of drugs compared individually with placebo. One limitation is that the individual trials lacked information on headache classification, so the proportion of migraine versus other types of headaches among the subjects is unknown. However, it is conceivable that most of the patients had migraine, as the prevalence of headache among placebo patients (12.4 percent) is similar to the reported prevalence of migraine in the general population. (See  <a class="medical medical_review" href="/z/d/html/3348.html" rel="external">"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults", section on 'Epidemiology'</a>.)</p><p class="headingAnchor" id="H5"><span class="h3">Beta blockers</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">Metoprolol</a>, <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a>, and <a class="drug drug_general" data-topicid="9997" href="/z/d/drug information/9997.html" rel="external">timolol</a> are established as effective for migraine prevention, while <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a> and <a class="drug drug_general" data-topicid="9672" href="/z/d/drug information/9672.html" rel="external">nadolol</a> are probably effective [<a href="#rid2">2</a>].</p><p>Our suggested doses for migraine prevention with beta blockers are as follows [<a href="#rid11">11,22,23</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">Propranolol</a> in two divided doses starting at 40 mg daily; dose range 40 to 240 mg daily</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">Metoprolol</a> in two divided doses starting at 50 mg daily; dose range 50 to 200 mg daily</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9672" href="/z/d/drug information/9672.html" rel="external">Nadolol</a> starting at 20 mg once a day; dose range 20 to 240 mg daily</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">Atenolol</a> starting at 25 mg daily; dose range 25 to 100 mg once daily</p><p></p><p>Although we generally do not use <a class="drug drug_general" data-topicid="9997" href="/z/d/drug information/9997.html" rel="external">timolol</a> for migraine prevention, it can be started at 5 mg once daily; the dose range is 10 to 30 mg daily given in two divided doses.</p><p>It can take several weeks for headache improvement to accrue with these drugs [<a href="#rid24">24</a>]; the dose should be titrated and maintained for at least three months before deeming the medication a failure.</p><p>We suggest <strong>not</strong> using beta blockers as initial therapy for migraine prevention in patients over age 60 and in smokers. Compared with other antihypertensive drugs in the primary treatment of hypertension, beta blockers may be associated with a higher rate of stroke and other cardiovascular events. (See  <a class="medical medical_review" href="/z/d/html/3869.html" rel="external">"Choice of drug therapy in primary (essential) hypertension"</a>.)</p><p>The use of beta blockers may be also limited in patients with erectile dysfunction, peripheral vascular disease, Raynaud phenomenon, and patients with baseline bradycardia or low blood pressure. They must be used cautiously as well in patients with asthma, diabetes mellitus, or depression, and in those with cardiac conduction disturbances or sinus node dysfunction. (See  <a class="medical medical_review" href="/z/d/html/967.html" rel="external">"Major side effects of beta blockers"</a>.)</p><p class="headingAnchor" id="H6"><span class="h3">Calcium channel blockers</span><span class="headingEndMark"> — </span>Calcium channel blockers are used for migraine prevention. However, the data supporting the efficacy of calcium channel blockers are weak and conflicting [<a href="#rid2">2,11</a>]. Two methodologically flawed studies showed a small but significant effect of <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a> (in three divided doses starting at 120 mg daily, dose range 120 to 240 mg daily) for migraine prevention [<a href="#rid25">25,26</a>]. If there is no response at lower doses, or if tolerance develops, verapamil can be increased to 480 mg per day in divided doses as tolerated; increased vigilance for bradycardia and heart block is mandatory with higher verapamil doses. </p><p><a class="drug drug_general" data-topicid="8869" href="/z/d/drug information/8869.html" rel="external">Flunarizine</a>, a nonspecific calcium channel blocker, also has some evidence of efficacy [<a href="#rid3">3,11</a>]. Based on several controlled studies, the recommended dose of flunarizine is 5 to 10 mg daily. Flunarizine is not available in the United States.</p><p>Tolerance may develop with calcium channel blockers; it occurred after eight weeks of successful therapy in 42 percent of those treated with <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a>, 49 percent treated with <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a>, and 4 percent treated with <a class="drug drug_general" data-topicid="9702" href="/z/d/drug information/9702.html" rel="external">nimodipine</a> in one report [<a href="#rid27">27</a>]. Tolerance may be overcome by increasing the dose of medication, or by switching to a different calcium channel blocker.</p><p class="headingAnchor" id="H7"><span class="h3">ACE inhibitors/ARBs</span><span class="headingEndMark"> — </span>A double-blind crossover study of 60 patients with two to six migraine episodes per month found that the ACE inhibitor <a class="drug drug_general" data-topicid="9565" href="/z/d/drug information/9565.html" rel="external">lisinopril</a> (10 mg/day for one week, then 20 mg/day) significantly reduced the number of hours and days with headache and headache severity compared with placebo [<a href="#rid28">28</a>]. </p><p><a class="drug drug_general" data-topicid="8670" href="/z/d/drug information/8670.html" rel="external">Candesartan</a> is an ARB that was found to be effective in two blinded crossover trials [<a href="#rid19">19,20</a>]. Approximately 40 percent of patients in both studies were responders to candesartan used at 16 mg once daily. </p><p>However, the small size and single-center crossover design of these trials prevent definitive conclusions regarding the effectiveness of <a class="drug drug_general" data-topicid="9565" href="/z/d/drug information/9565.html" rel="external">lisinopril</a> and <a class="drug drug_general" data-topicid="8670" href="/z/d/drug information/8670.html" rel="external">candesartan</a> for migraine prevention. </p><p class="headingAnchor" id="H8"><span class="h2">Antidepressants</span><span class="headingEndMark"> — </span>In a systematic review of prospective double-blind, randomized controlled trials of medications for migraine prevention, the tricyclic antidepressant <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a> (starting dose 10 mg at bedtime, dose range 20 to 50 mg at bedtime) was effective for migraine prevention in four trials [<a href="#rid11">11</a>]. Doses ranging from 10 to 100 mg per day are used in clinical practice. In other trials, the serotonin-norepinephrine reuptake inhibitor <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a> (starting at 37.5 mg once a day, dose range 75 to 150 mg once a day) was also effective as prevention for migraine [<a href="#rid11">11</a>]. Similarly, a 2012 guideline from the American Academy of Neurology (AAN) concluded that amitriptyline and venlafaxine are probably effective for migraine prevention [<a href="#rid2">2</a>].</p><p>Although other tricyclic antidepressants (eg, <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">nortriptyline</a> and <a class="drug drug_general" data-topicid="9832" href="/z/d/drug information/9832.html" rel="external">protriptyline</a>) are used in clinical practice, <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a> is the only tricyclic that has proven efficacy for migraine; there are insufficient data regarding the other tricyclics [<a href="#rid9">9</a>].</p><p>Side effects are common with tricyclic antidepressants. Most are sedating, particularly <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a> and <a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">doxepin</a>. Therefore, these drugs are usually used at bedtime and started at a low dose. Additional side effects of tricyclics include dry mouth, constipation, tachycardia, palpitations, orthostatic hypotension, weight gain, blurred vision, and urinary retention. Confusion can occur, particularly in older adults. (See  <a class="medical medical_review" href="/z/d/html/1717.html" rel="external">"Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects"</a>.)</p><p><a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">Venlafaxine</a> is used by the author for patients with migraine who have comorbid panic disorder, generalized anxiety disorder, persistent postural perceptual dizziness, or social anxiety disorder. (See  <a class="medical medical_review" href="/z/d/html/108804.html" rel="external">"Management of panic disorder with or without agoraphobia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/505.html" rel="external">"Pharmacotherapy for social anxiety disorder in adults"</a> and  <a class="medical medical_review" href="/z/d/html/101879.html" rel="external">"Generalized anxiety disorder in adults: Management"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Anticonvulsants</span><span class="headingEndMark"> — </span>The anticonvulsants sodium <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> and <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> are more effective than placebo for reducing the frequency of migraine attacks [<a href="#rid11">11,29</a>]. A 2012 guideline from the AAN concluded that topiramate and sodium valproate are established as effective for migraine prevention, while evidence is insufficient to determine the effectiveness of <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H12"><span class="h3">Topiramate</span><span class="headingEndMark"> — </span>Several placebo-controlled studies, a systematic review, and a meta-analysis have found that <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> is effective preventive therapy for migraine [<a href="#rid18">18,30-33</a>]. The starting topiramate dose in most of these studies was 25 mg/day, with slow titration by 25 to 50 mg/week to the maximum of 100 mg twice daily or the highest tolerated dose.</p><p>The two largest randomized trials of <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> for migraine each evaluated over 460 patients [<a href="#rid30">30,31</a>]. The following observations emerged from these trials [<a href="#rid30">30,31</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The mean monthly migraine frequency decreased significantly for patients receiving <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> at either 100 or 200 mg/day compared with placebo. For patients receiving topiramate at 50 mg/day, the reduction in migraine frequency did not achieve statistical significance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Significant reductions in migraine frequency occurred within the first month at <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> doses of 100 and 200 mg/day. The responder rate (proportion of patients with a ≥50 percent reduction in mean migraine frequency) for these doses was about 50 percent of treated patients. The effectiveness of topiramate at these doses was maintained for the entire double-blind treatment phase.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">Topiramate</a> treatment-related adverse events, generally mild to moderate in severity, included paresthesia, fatigue, anorexia, diarrhea, weight loss, hypesthesia, memory difficulty, language problems, difficulty with concentration, nausea, and taste perversion. Of these, paresthesia was the most common, occurring in about half of patients receiving topiramate at 100 or 200 mg/day. Weight loss is a unique side effect of this drug, and it occurred in 9 to 12 percent of patients taking 100 to 200 mg/day of topiramate.</p><p></p><p>Adverse events with <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> were more frequent with the 200 mg/day dose in controlled trials, leading to withdrawal of therapy in up to 30 percent of patients [<a href="#rid11">11</a>]. Therefore, some experts recommend using topiramate at no more than 100 mg/day for migraine prevention. We suggest not using topiramate during pregnancy, since topiramate is associated with an increased risk of facial clefts and may increase the risk of low birth weight (see  <a class="medical medical_review" href="/z/d/html/2218.html" rel="external">"Risks associated with epilepsy during pregnancy and the postpartum period", section on 'Topiramate'</a>). A more complete review of adverse effects is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Topiramate'</a>.)</p><p>Data from one trial suggest that <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> has residual benefit for migraine that persists for up to six months after the drug is discontinued [<a href="#rid32">32</a>].</p><p>Limited data from comparative trials suggest that <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> is as effective as <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> for episodic migraine prevention, and may have a modest advantage over <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> [<a href="#rid33">33</a>]. Patients should be counseled that topiramate doses greater than 100 mg may induce estrogen metabolism and impact the efficacy of oral contraception.</p><p class="headingAnchor" id="H457019427"><span class="h3">Valproate</span><span class="headingEndMark"> — </span>A review of three trials evaluating valproate products (divalproex sodium, sodium valproate, and <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproic acid</a>) at doses ranging from 500 to 1500 mg daily for migraine prevention found that valproate was significantly more effective than placebo as measured by the number of patients experiencing a ≥50 percent reduction in migraine frequency (OR 2.74, 95% CI 1.48-5.08) [<a href="#rid11">11</a>]. Subsequent systematic reviews reached similar conclusions [<a href="#rid18">18,34</a>].</p><p><a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">Valproate</a> can work well for migraine prevention at doses less than 1000 mg/day; doses up to 1500 mg/day are sometimes needed to achieve a response, but higher doses are associated with the potential for more adverse effects. Valproate can cause nausea, somnolence, tremor, dizziness, weight gain, and hair loss. It is contraindicated in pregnancy because of teratogenicity. In addition, valproate has been linked to lower intelligence quotient scores among children with prenatal valproate exposure (see  <a class="medical medical_review" href="/z/d/html/2218.html" rel="external">"Risks associated with epilepsy during pregnancy and the postpartum period", section on 'Effects of ASMs on the fetus and child'</a>). Therefore, valproate should not be used by females of childbearing age for headache prevention [<a href="#rid35">35</a>]. A more complete review of adverse effects is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Valproate'</a>.)</p><p class="headingAnchor" id="H158088962"><span class="h3">Gabapentin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">Gabapentin</a> is used for migraine prevention based on clinical experience as well as society guideline endorsement [<a href="#rid4">4</a>]. However, a systematic review of five controlled trials found that gabapentin was not efficacious for episodic migraine prevention in adults [<a href="#rid36">36</a>]. In addition, a 20-week trial of 523 patients reported no significant difference between treatment with <a class="drug drug_general" data-topicid="16486" href="/z/d/drug information/16486.html" rel="external">gabapentin enacarbil</a> (the prodrug of gabapentin) and placebo in change from baseline in the number of migraine headache days during the last four weeks of treatment [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H2010410496"><span class="h2">CGRP antagonists</span><span class="headingEndMark"> — </span>Calcitonin gene-related peptide (CGRP) is a therapeutic target in migraine because of its role in mediating trigeminovascular pain transmission and neurogenic inflammation. (See  <a class="medical medical_review" href="/z/d/html/3348.html" rel="external">"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults", section on 'Role of calcitonin gene-related peptide'</a>.)</p><p>There are several CGRP antagonists available in different formulations  (<a class="graphic graphic_table graphicRef141581" href="/z/d/graphic/141581.html" rel="external">table 2</a>). Large molecules in the form of monoclonal antibodies directed against the CGRP receptor or ligand are given by injection for migraine prevention. Small-molecule CGRP antagonists ("gepants") are oral agents first shown effective for acute migraine treatment. <a class="drug drug_general" data-topicid="127256" href="/z/d/drug information/127256.html" rel="external">Rimegepant</a> and <a class="drug drug_general" data-topicid="133172" href="/z/d/drug information/133172.html" rel="external">atogepant</a> are orally formulated gepants that have also shown benefit for migraine prevention [<a href="#rid38">38</a>]. The United States Food and Drug Administration (FDA) approved the monoclonal antibody CGRP antagonists <a class="drug drug_general" data-topicid="117927" href="/z/d/drug information/117927.html" rel="external">erenumab</a> [<a href="#rid39">39</a>], <a class="drug drug_general" data-topicid="119043" href="/z/d/drug information/119043.html" rel="external">fremanezumab</a> [<a href="#rid40">40</a>], and <a class="drug drug_general" data-topicid="119169" href="/z/d/drug information/119169.html" rel="external">galcanezumab</a> [<a href="#rid41">41</a>] in 2018, <a class="drug drug_general" data-topicid="127182" href="/z/d/drug information/127182.html" rel="external">eptinezumab</a> [<a href="#rid42">42</a>] in 2020, and rimegepant and atogepant in 2021 [<a href="#rid43">43,44</a>] for migraine prevention.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erenumab</strong> – <a class="drug drug_general" data-topicid="117927" href="/z/d/drug information/117927.html" rel="external">Erenumab</a>, a human monoclonal antibody that binds to and inhibits the CGRP receptor, was modestly effective for migraine prevention in a placebo-controlled trial of over 900 adults with episodic migraine [<a href="#rid45">45</a>]. The trial randomly assigned subjects in a 1:1:1 ratio to subcutaneous injections of erenumab 70 mg, erenumab 140 mg, or placebo monthly for six months. At baseline, the mean number of migraine days per month was 8.3 in the overall population. At months four through six, the number of migraine days per month was reduced by 3.2 in the 70 mg erenumab group, 3.7 in the 140 mg erenumab group, and 1.8 in the placebo group. The rates of adverse events were similar between the erenumab and placebo groups.</p><p></p><p class="bulletIndent1">Another trial evaluated 246 subjects with treatment-resistant episodic migraine who had failed to respond to or did not tolerate between two and four previous migraine preventive medications [<a href="#rid13">13</a>]. Subjects were randomly assigned to receive <a class="drug drug_general" data-topicid="117927" href="/z/d/drug information/117927.html" rel="external">erenumab</a> 140 mg or placebo by subcutaneous injection every four weeks. At 12 weeks, the proportion of patients who had a 50 percent or more reduction in the mean number of monthly migraine days was greater for the group assigned to erenumab compared with the group assigned to placebo (30 versus 17 percent; OR 2.7, 95% CI 1.4-5.2; absolute risk difference 13 percent). In an open-label extension phase of this study, the response rate at 64 weeks increased in those switching from placebo to erenumab and in those who continued erenumab (50 and 44 percent, respectively) [<a href="#rid46">46</a>]. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="117927" href="/z/d/drug information/117927.html" rel="external">Erenumab</a> appears to be effective for patients with episodic migraine either with or without aura. In a secondary analysis of four clinical trials involving more than 2000 patients with episodic migraine, the effectiveness of erenumab at 70 mg or 140 mg over placebo, as assessed by the proportion of patients with at least a 50 percent reduction in the number of monthly migraine days by 12 weeks, was sustained when results were stratified by patients with migraine with (45 percent for 70 mg, 46 percent for 140 mg, 32 percent for placebo) and without aura (37 percent for 70 mg, 51 percent for 140 mg, 25 percent for placebo) [<a href="#rid47">47</a>]. Adverse effects were mild and similar between groups.</p><p></p><p class="bulletIndent1">We use <a class="drug drug_general" data-topicid="117927" href="/z/d/drug information/117927.html" rel="external">erenumab</a> at 140 mg dosing; the risk of adverse events is similar for 70 and 140 mg doses in clinical trials, and some observational data suggest patients who respond initially to the 70 mg dose require a dose increase to 140 mg for sustained benefit [<a href="#rid48">48</a>]. Erenumab is administered as a subcutaneous injection once monthly in the abdomen, thigh, or upper arm. Injection site reactions and constipation are the most common adverse effects [<a href="#rid49">49</a>]. Hypertension, at times causing serious complications, has also been reported [<a href="#rid50">50</a>]. Patients treated with erenumab should be monitored for the onset or worsening of hypertension. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fremanezumab</strong> – <a class="drug drug_general" data-topicid="119043" href="/z/d/drug information/119043.html" rel="external">Fremanezumab</a>, a human monoclonal antibody that binds to both isoforms of the CGRP ligand, is effective for prevention of episodic migraine [<a href="#rid14">14,51</a>]. One trial randomly assigned 875 adults with episodic migraine in a 1:1:1 ratio to subcutaneous fremanezumab 225 mg monthly for three months, a single dose of fremanezumab 675 mg (intended to support a quarterly dose regimen), or placebo [<a href="#rid51">51</a>]. At three months compared with placebo, the mean number of migraine days per month decreased by 1.5 in the fremanezumab monthly dose group and by 1.3 days in the single higher dose group. The proportion of patients with at least a 50 percent reduction in the mean number of monthly migraine days was 48 percent in the fremanezumab monthly dose group and 44 percent in the fremanezumab single higher dose group, compared with 28 percent for the placebo group. At three months, patients assigned to placebo were rerandomized to receive monthly or quarterly fremanezumab injections. At 12 months, the reduction in baseline migraine burden was sustained in both monthly and quarterly fremanezumab dosing regimens by 5.1 and 5.2 days per month, respectively [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1">The recommended dose of <a class="drug drug_general" data-topicid="119043" href="/z/d/drug information/119043.html" rel="external">fremanezumab</a> is 225 mg once monthly or 675 mg (given as three consecutive injections of 225 mg each) every three months administered subcutaneously in the abdomen, thigh, or upper arm. The most common adverse effects are injection site reactions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Galcanezumab</strong> – <a class="drug drug_general" data-topicid="119169" href="/z/d/drug information/119169.html" rel="external">Galcanezumab</a>, a human monoclonal antibody that binds to the CGRP ligand, is also effective for episodic migraine prevention, as demonstrated in several placebo-controlled trials [<a href="#rid53">53-55</a>]. As an example, one of these trials randomly assigned 858 patients with episodic migraine to monthly subcutaneous galcanezumab 120 mg, galcanezumab 240 mg, or placebo in a 1:1:2 ratio [<a href="#rid56">56</a>]. At six months, the mean number of migraine days per month decreased by 4.7 and 4.6 for the galcanezumab 120 and 240 mg groups, respectively, compared with 2.8 days for the placebo group. In another trial of 462 migraine patients who were previously nonresponders to other standard preventive therapies, those assigned to galcanezumab had fewer migraines compared with placebo (4.1 versus 1.0 fewer migraine days per month) [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="119169" href="/z/d/drug information/119169.html" rel="external">Galcanezumab</a> treatment is started with a loading dose of 240 mg, given as two consecutive doses of 120 mg each, followed by monthly doses of 120 mg, administered subcutaneously in the thigh, upper arm, or buttocks. Injection site reactions were the most common adverse events in clinical trials.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eptinezumab</strong> – <a class="drug drug_general" data-topicid="127182" href="/z/d/drug information/127182.html" rel="external">Eptinezumab</a> is a monoclonal antibody that binds to both isoforms of the CGRP ligand. Data from randomized trials support its efficacy for prevention of migraine [<a href="#rid57">57-59</a>]. The PROMISE-1 trial randomly assigned 888 patients in a 1:1:1:1 ratio to intravenous (IV) eptinezumab 30 mg, 100 mg, 300 mg, or placebo administered every 12 weeks for up to four IV doses [<a href="#rid57">57</a>]. The reduction in mean monthly migraine days from baseline was approximately 4 for each of the eptinezumab dose groups, compared with approximately 3 days for the placebo group. In addition, a ≥50 percent reduction in migraine days was achieved by more patients in the 100 mg and 300 mg eptinezumab groups (50 and 56 percent, compared with 38 percent in the placebo group). </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="127182" href="/z/d/drug information/127182.html" rel="external">Eptinezumab</a> given during a migraine may also shorten the time to headache resolution. In a trial of 480 patients with frequent episodic migraine, those assigned eptinezumab 100 mg within six hours of migraine onset were likelier to be headache free at two hours than those who received placebo (24 versus 12 percent; OR 2.27, 95% CI 1.4-3.7) [<a href="#rid60">60</a>]. In the eptinezumab group, use of rescue medications within the subsequent 48 hours was less frequent (35 versus 64 percent) and the interval to the next migraine headache was longer (10 versus 5 days).</p><p></p><p class="bulletIndent1">The recommended dose of <a class="drug drug_general" data-topicid="127182" href="/z/d/drug information/127182.html" rel="external">eptinezumab</a> is 100 mg given as an IV infusion over approximately 30 minutes every three months [<a href="#rid61">61</a>]. The label notes that some patients may benefit from a 300 mg dose. Adverse effects associated with eptinezumab include upper respiratory tract infections, hypersensitivity, and fatigue. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rimegepant</strong> – <a class="drug drug_general" data-topicid="127256" href="/z/d/drug information/127256.html" rel="external">Rimegepant</a> is a small-molecule CGRP receptor antagonist administered orally that is effective for migraine prevention. In a trial of 1591 patients with migraine, those assigned to receive rimegepant 75 mg every other day for 12 weeks had a greater reduction in migraine days per month than those assigned to placebo (-4.3 versus -3.5 days; difference -0.8 days, 95% CI -1.46 to -0.2) [<a href="#rid62">62</a>]. The response rate in those with ≥50 percent reduction in moderate or severe monthly migraine days was also higher among those who received rimegepant (49 versus 41 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atogepant</strong> – <a class="drug drug_general" data-topicid="133172" href="/z/d/drug information/133172.html" rel="external">Atogepant</a> is an oral small-molecule CGRP receptor antagonist that appeared to be effective in clinical trials for migraine prevention [<a href="#rid38">38,63</a>]. In one study, 834 patients with 4 to 14 migraine days per month received atogepant daily regimens from 10 mg once daily up to 60 mg twice daily or placebo for 12 weeks. Atogepant treatment regimens were associated with a reduction of migraines by nearly four days per month independent of dose regimen [<a href="#rid38">38</a>]. However, adverse effects were more common in higher dose regimens with nausea as the most common and none were serious. Another study of 873 patients with episodic migraine similarly found that patients assigned to atogepant 10 mg, 30 mg, or 60 mg once daily for 12 weeks had fewer migraine days per month than those assigned to placebo [<a href="#rid63">63</a>]. In addition, patients assigned to each atogepant dosing regimen were likelier to achieve at least a 50 percent reduction in the three-month mean number of monthly migraine days (56 to 61 percent for atogepant regimens versus 29 percent for placebo). In the initial trial and subsequent open-label extension, the most common adverse events in patients taking atogepant were nasopharyngitis or sinusitis, upper respiratory tract infections, lower urinary tract infections, constipation, and nausea [<a href="#rid63">63,64</a>].</p><p></p><p>The selection of specific agent should be individualized according to response to prior therapy, patient and clinician preferences regarding dosing routes and regimens, and cost. Several agents are given subcutaneously every month, and an injection once every three months is available for subcutaneous <a class="drug drug_general" data-topicid="119043" href="/z/d/drug information/119043.html" rel="external">fremanezumab</a> and intravenous <a class="drug drug_general" data-topicid="127182" href="/z/d/drug information/127182.html" rel="external">eptinezumab</a>. <a class="drug drug_general" data-topicid="133172" href="/z/d/drug information/133172.html" rel="external">Atogepant</a> and <a class="drug drug_general" data-topicid="127256" href="/z/d/drug information/127256.html" rel="external">rimegepant</a> are oral agents given daily or every other day, respectively. Atogepant is also approved for use for patients with chronic migraine, and <a class="drug drug_general" data-topicid="119169" href="/z/d/drug information/119169.html" rel="external">galcanezumab</a> may be used for patients with episodic cluster headache. In a network meta-analysis of clinical trials, all agents were found to be more effective than placebo [<a href="#rid65">65</a>]. The reduction in monthly migraine days was highest with fremanezumab given monthly, followed by <a class="drug drug_general" data-topicid="117927" href="/z/d/drug information/117927.html" rel="external">erenumab</a>, galcanezumab, and atogepant. The reduction in the use of acute medications was highest among patients who received erenumab, followed by monthly fremanezumab and atogepant. Adverse effect rates were similar to placebo for most agents except galcanezumab and quarterly fremanezumab.</p><p>There is little evidence to guide the use of the CGRP antagonists in specific populations (eg, children, older adults, and pregnant or lactating patients). They should be avoided for those who are pregnant or likely to become pregnant and for individuals with recent cardiovascular or cerebrovascular ischemic events, since CGRP has theoretical cardioprotective and vasodilatory effects [<a href="#rid12">12,66</a>]. Although probably unrelated to treatment, there were three deaths in clinical trial subjects who received CGRP monoclonal antibodies [<a href="#rid51">51,67,68</a>]. Additional concerns have been raised about the potential for adverse cardiovascular, pulmonary, and psychiatric effects with CGRP antagonists [<a href="#rid69">69</a>], even though these were not observed in randomized trials [<a href="#rid70">70-72</a>]. Cases of angioedema and anaphylaxis have also been reported [<a href="#rid73">73,74</a>]. More data are needed regarding the long-term safety of this class of medications [<a href="#rid69">69</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Other agents</span><span class="headingEndMark"> — </span>A number of other agents have been studied for migraine prevention [<a href="#rid75">75-79</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Botulinum toxin</strong> – Several randomized placebo-controlled trials have found no consistent, statistically significant benefits for botulinum toxin injection in the treatment of episodic migraine headache [<a href="#rid80">80-82</a>]. In addition, an evidence-based review published in 2008 by the AAN concluded that botulinum toxin is probably ineffective for the treatment of episodic migraine [<a href="#rid83">83</a>]. A 2010 systematic review reached a similar conclusion [<a href="#rid11">11</a>]. Given these data, the use of botulinum toxin therapy is <strong>not</strong> recommended for the preventive treatment of <strong>episodic</strong> migraine.</p><p></p><p class="bulletIndent1">In contrast, there is evidence that botulinum toxin type A (<a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a>) injection is effective for the treatment of <strong>chronic</strong> migraine (ie, headache on ≥15 days per month for at least three months, with at least 8 of the 15 headaches per month fulfilling criteria for migraine without aura). The utility of botulinum toxin injection for chronic migraine is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3337.html" rel="external">"Chronic migraine", section on 'Second- and third-line agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Coenzyme Q10</strong> – Interest in coenzyme Q10 (CoQ10) for migraine treatment has been sparked by the potential role of mitochondrial dysfunction in migraine pathogenesis [<a href="#rid84">84,85</a>]. In a small, randomized controlled trial of 42 patients with migraine, CoQ10 was effective for migraine prevention; significantly more patients treated with CoQ10 (100 mg three times daily) experienced a ≥50 percent reduction in attack frequency at three months than patients treated with placebo (47.6 versus 14.4 percent) [<a href="#rid86">86</a>]. CoQ10 treatment was well tolerated. Larger clinical trials are needed to confirm the benefit of CoQ10 for migraine prevention.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9861" href="/z/d/drug information/9861.html" rel="external">Riboflavin</a> – Riboflavin used to improve energy metabolism may support the contribution of mitochondrial dysfunction in the development of migraine [<a href="#rid85">85</a>]. A randomized, double-blind, placebo-controlled trial of 55 patients who were suffering from two to eight migraines per month found that the administration of oral vitamin B2 (riboflavin) at a dose of 400 mg/day compared with placebo resulted in a significantly higher proportion of patients with greater than 50 percent improvement in the frequency of headaches (54 versus 19 percent), headache days (57 versus 15 percent), and the migraine index (headache days and mean severity 39 versus 8 percent) [<a href="#rid87">87</a>]. The benefits only became significant after three months of therapy. Riboflavin was well tolerated. Additional studies are needed to confirm these results and to determine the optimum dose and patient population most likely to benefit.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Feverfew</strong> – Feverfew has been the herbal remedy most studied for the prevention of migraine, but evidence regarding benefit is conflicting. A 2015 systematic review of feverfew for migraine prevention found six randomized controlled trials with 561 patients that met the inclusion criteria [<a href="#rid88">88</a>]. Four of the included trials [<a href="#rid89">89-92</a>] found that feverfew was beneficial, while two trials [<a href="#rid93">93,94</a>] found no significant difference between feverfew and placebo [<a href="#rid88">88</a>]. There were no major adverse effects associated with the use of feverfew. A planned meta-analysis was not performed because of heterogeneity among the trials and the absence of common outcome measures. All trials were considered to be at unclear or high risk of bias due to small sample size. The review concluded that larger rigorous trials are needed before firm conclusions can be drawn about the effectiveness of feverfew for migraine headache. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Magnesium</strong> – There is only limited evidence supporting magnesium supplementation for migraine prevention in adults [<a href="#rid95">95</a>]. Several small randomized controlled trials using variable formulations of oral magnesium produced mixed results, with three trials finding a statistically significant benefit for magnesium [<a href="#rid96">96-98</a>], and one trial finding no benefit [<a href="#rid99">99</a>]. Magnesium is typically used at 400 to 600 mg daily for migraine prevention [<a href="#rid75">75</a>]. Diarrhea and gastrointestinal discomfort were the most common side effects of magnesium supplementation in these trials.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Melatonin</strong> – Small, short-term randomized controlled trials evaluating melatonin for episodic migraine prevention have provided conflicting results. One such trial found that melatonin 2 mg (extended release) was <strong>not</strong> more effective than placebo for reducing headache frequency [<a href="#rid100">100</a>], while another trial reported that melatonin 3 mg (immediate release) was more effective than placebo, and equally as effective as <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a>, for reducing headache frequency [<a href="#rid101">101</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonsteroidal anti-inflammatory drugs</strong> – A number of older randomized controlled trials have found that <a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">naproxen</a>, a nonsteroidal anti-inflammatory drug (NSAID), is moderately more effective than placebo for migraine prevention [<a href="#rid102">102-106</a>]. A systematic review and meta-analysis from the US Agency for Health Care Policy and Research (AHCPR) included 23 controlled trials of 10 different NSAIDs indexed from 1966 through 1996 [<a href="#rid107">107</a>]. The evidence was strongest for naproxen, with multiple placebo-controlled trials showing a moderate reduction in headache symptoms [<a href="#rid107">107</a>]. Only one trial supported the efficacy of <a class="drug drug_general" data-topicid="8590" href="/z/d/drug information/8590.html" rel="external">ketoprofen</a> [<a href="#rid108">108</a>], while the evidence was less certain for <a class="drug drug_general" data-topicid="8440" href="/z/d/drug information/8440.html" rel="external">fenoprofen</a>. The AHCPR review identified no controlled trials of <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a> [<a href="#rid107">107</a>].</p><p></p><p class="bulletIndent1">The use of NSAIDs for the treatment of acute migraine headache is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3347.html" rel="external">"Acute treatment of migraine in adults", section on 'Nonsteroidal anti-inflammatory drugs'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Simvastatin</strong><strong> plus vitamin D</strong> – In a randomized controlled trial of 57 adults with episodic migraine, in which participants continued their pre-study abortive and prophylactic migraine medications, treatment with <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a> (20 mg twice daily) plus <a class="drug drug_general" data-topicid="10117" href="/z/d/drug information/10117.html" rel="external">vitamin D3</a> (1000 international units twice daily) was superior to placebo over a 24-week intervention period for reduction in the number of days with migraine headache and some secondary outcome measures [<a href="#rid109">109</a>]. The small size of this trial limits the strength of the findings.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hormonal contraceptives</strong> – Hormonal contraceptive agents may be used for migraine prophylaxis for patients with estrogen-associated migraine. These agents are used to suppress migraines triggered by cyclic fluctuation of estrogen levels. (See  <a class="medical medical_review" href="/z/d/html/5441.html" rel="external">"Estrogen-associated migraine headache, including menstrual migraine", section on 'Preventive therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pizotifen</strong> – A systematic review identified five placebo-controlled trials evaluating the serotonin blocker <a class="drug drug_general" data-topicid="10091" href="/z/d/drug information/10091.html" rel="external">pizotifen</a> for migraine prevention [<a href="#rid11">11</a>]. Although the trials were heterogeneous and could not be combined for meta-analysis, all five found that pizotifen (starting at 0.5 mg daily, dosage range 1.5 mg daily to 3 mg daily in three divided doses) was superior to placebo. Weight gain and sedation were the most common adverse events in these trials. Pizotifen is not licensed for use in the United States.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Butterbur</strong> – An extract of butterbur (Petasites hybridus) root, a perennial shrub, is an herbal medicine that is marketed as a food supplement in the United States. The extract was previously registered as a licensed pharmaceutical medicine in Germany (Petadolex), but the registration expired and it is no longer available in Germany [<a href="#rid110">110</a>]. At least two small placebo-controlled clinical trials found some efficacy for Petasites extract in migraine prevention [<a href="#rid111">111-113</a>]. In the larger of these studies, Petasites at a dose of 150 mg daily (given in two divided doses) but <strong>not</strong> 100 mg daily was effective and well tolerated as preventive therapy for migraine. Gastrointestinal upset, predominately burping, was the most common side effect [<a href="#rid113">113</a>].</p><p></p><p class="bulletIndent1">Butterbur contains pyrrolizidine alkaloids that are hepatotoxic and potentially carcinogenic; they are removed from the commercially prepared Petasites root extract. However, concerns persist due to the lack of long-term safety data and the absence of a regulated product. Therefore, we no longer suggest the use of butterbur-containing compounds.</p><p></p><p class="headingAnchor" id="H23"><span class="h2">Nonpharmacologic interventions</span><span class="headingEndMark"> — </span>Nonpharmacologic therapies with at least moderate-quality evidence suggesting benefit for migraine headache prevention include aerobic exercise, biofeedback, other forms of relaxation training, cognitive-behavioral therapies, acupuncture, and transcutaneous electrical nerve stimulation [<a href="#rid114">114-119</a>]. Several of these are discussed in greater detail in the sections that follow. (See <a class="local">'Acupuncture'</a> below and <a class="local">'Neuromodulation'</a> below and <a class="local">'Desensitizing triggers'</a> below.)</p><p>Therapeutic lifestyle measures may be beneficial for controlling migraine, including good sleep hygiene, routine meal schedules, regular aerobic exercise, and managing migraine triggers. (See <a class="local">'Lifestyle measures'</a> above.) </p><p class="headingAnchor" id="H25"><span class="h3">Acupuncture</span><span class="headingEndMark"> — </span>Some evidence suggests that classic acupuncture may have modest benefits for migraine headache prevention, but data from clinical trials and systematic reviews are mixed [<a href="#rid120">120-123</a>].</p><p>Acupuncture appears to be more effective than oral pharmacologic placebos, but probably not more effective than sham needling or traditional medical therapy [<a href="#rid124">124</a>]. A randomized controlled trial with 302 patients found that acupuncture was <strong>not</strong> more effective than sham acupuncture (needling at points distant from "true" treatment points and using fewer needles) in reducing migraine headaches [<a href="#rid125">125</a>]. However, both acupuncture and sham acupuncture were significantly more effective in reducing days with headache than assignment to a wait-list control group. In another randomized controlled trial with 794 patients available for intention-to-treat analysis, the reduction in migraine headache days at 23 to 25 weeks for acupuncture, sham acupuncture, or standard medical therapy groups (mean reduction 2.3, 1.5, and 2.1 days, respectively) was statistically significant when compared with baseline, but nonsignificant across treatment groups [<a href="#rid126">126</a>].</p><p>Although the explanation for these results is uncertain, one hypothesis is that, compared with oral pharmacologic placebos, the placebo effect of sham acupuncture is enhanced by contextual factors such as more elaborate treatment rituals and higher levels of attention and physical contact [<a href="#rid120">120,127,128</a>]. Headache improvement related to nonspecific physiologic effects of needling is another possible mechanism.</p><p class="headingAnchor" id="H344989030"><span class="h3">Neuromodulation</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transcutaneous supraorbital nerve stimulation</strong> – Although data are limited, the findings of a controlled trial conducted at five tertiary headache centers in Belgium suggest that treatment with a supraorbital transcutaneous electrical nerve stimulator is beneficial for patients with episodic migraine [<a href="#rid129">129</a>]. The trial randomly assigned 69 adults with migraine (with or without aura) to active or sham stimulation for 20 minutes daily for three months. Exclusion criteria included the use of preventive treatment for migraine in the three months prior to enrollment. At three months of treatment, the responder rate, defined as the percentage of subjects with a ≥50 percent reduction in migraine days per month, was significantly higher for the active stimulation compared with the sham stimulation group (38.2 versus 12.1 percent), as was the mean reduction in monthly migraine days (-2.1 versus +0.3 days). There were no adverse events in either group. Limitations to this trial include small effect size, low patient numbers, and uncertainty in concealing treatment allocation, given that active stimulation causes intense paresthesia. The device used in this trial is approved for marketing in the United States, Canada, Europe, and several additional countries. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transcranial magnetic stimulation</strong> – Limited observational evidence suggests that single-pulse transcranial magnetic stimulation (sTMS) may be effective for migraine prevention. An open-label, prospective study of subjects with episodic and chronic migraine, with and without aura, assessed preventive (four pulses twice daily) and acute (three pulses repeated up to three times for each migraine attack) sTMS treatment over a 12-week period [<a href="#rid130">130</a>]. During weeks 9 through 12, the mean reduction of headache days was greater with TMS compared with an estimated placebo response derived from historical data (-2.75 versus -0.63 days). Adverse events were infrequent, but included lightheadedness, tingling, and tinnitus. In a meta-analysis of sham-controlled trials, repetitive TMS over the dorsolateral prefrontal cortex was associated with reduced functional disability and medication use but no improvement in pain intensity or headache days [<a href="#rid131">131</a>]. sTMS received FDA approval for the acute and prophylactic treatment of migraine in 2017.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vagal nerve stimulation</strong> – Neuromodulation by vagal nerve stimulation was associated with reduced headache burden in observational studies for patients with episodic migraine [<a href="#rid132">132,133</a>]. However, a clinical trial failed to confirm a benefit [<a href="#rid134">134</a>]. Additional studies are needed to identify the role of this intervention for patients with migraine.</p><p></p><p class="headingAnchor" id="H3325300128"><span class="h3">Desensitizing triggers</span><span class="headingEndMark"> — </span>Traditional teaching is that avoidance of known migraine trigger factors is a useful strategy for migraine prevention, but there is scant evidence to support this approach. Some studies suggest that avoidance of trigger factors may paradoxically lead to trigger sensitization, particularly since many known triggers cannot be completely avoided [<a href="#rid118">118,135</a>]. These reports suggest that coping with headache triggers is potentially a more valuable strategy than advice to avoid the triggers.</p><p>Learning to cope (LTC) is a behavioral method that involves graduated exposure to selected headache triggers to promote desensitization [<a href="#rid118">118</a>]. In a small, single-center randomized controlled trial of patients with migraine or tension-type headache, the group assigned to the LTC strategy had a significant reduction in both headache and medication use compared with the control group, while the group assigned to trigger avoidance had no significant reduction in headache or medication use [<a href="#rid136">136</a>]. A third group assigned to trigger avoidance plus cognitive-behavioral therapy had a significant reduction in headaches but not medication use. These data suggest that LTC is a better strategy than avoidance, but further study is needed to establish whether it is an effective and practical approach to migraine prevention.</p><p class="headingAnchor" id="H230975723"><span class="h3">Other interventions not recommended</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgery</strong> – Results from a single-center trial suggested that surgical removal of muscle or nerve tissue from headache "trigger sites" may be an effective treatment for select patients with frequent migraine headache [<a href="#rid137">137</a>]. However, the trial results have been received with skepticism by some headache experts due to small numbers and methodologic flaws including poor case definition and inadequate controls [<a href="#rid138">138</a>]. In addition, the proposed mechanism of benefit (trigger site deactivation) does not fit with current pathophysiologic models of migraine. Given the methodologic flaws in the study design [<a href="#rid138">138,139</a>], independent confirmation of benefit in more rigorous trials is needed. In addition, only a minority of patients with frequent migraine (those with identifiable trigger sites and a positive response to botulinum toxin injection) would appear to be candidates.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Closure of right-to-left cardiac shunt</strong> – There is conflicting evidence regarding a possible association of migraine with aura and right-to-left cardiac shunts in the setting of a patent foramen ovale (PFO) or an atrial septal defect (ASD), as reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/3348.html" rel="external">"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults", section on 'Right-to-left cardiac shunt'</a>.)</p><p></p><p class="bulletIndent1">However, clinical trials have failed to show that PFO/ASD closure is beneficial for migraine. The multicenter double-blind MIST trial enrolled 147 patients with a PFO who had frequent migraine with aura that was refractory to two types of preventive medication [<a href="#rid140">140</a>]. At six months, there was no difference between PFO device closure and sham treatment for the primary end point of headache cure, which was achieved in each treatment group by three patients (4 percent). Furthermore, the PFO closure group experienced more serious adverse events than the sham group. The smaller open-label PRIMA trial, which was stopped prematurely due to slow recruitment, compared PFO device closure with medical management among subjects with migraine with aura [<a href="#rid141">141</a>]. At one year, there was no difference between groups for reduction in monthly migraine days. </p><p></p><p class="bulletIndent1">In earlier reports, which were relatively small and largely retrospective, improvement in migraine after device closure of a PFO or an ASD was noted in some (but not all) studies [<a href="#rid142">142-152</a>]. Most of the patients treated with shunt closure were selected because of prior cryptogenic stroke or paradoxical embolism. A majority of study patients were treated with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>, which may have reduced migraine frequency.</p><p></p><p class="headingAnchor" id="H3283292913"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110285.html" rel="external">"Society guideline links: Migraine and other primary headache disorders"</a>.)</p><p class="headingAnchor" id="H28"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/112403.html" rel="external">"Patient education: Migraines in adults (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/734.html" rel="external">"Patient education: Migraines in adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/720.html" rel="external">"Patient education: Headache treatment in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H29"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for preventive treatments</strong> – We advise migraine prevention therapy for patients with migraine headaches that are not easily managed with acute therapies and who are at risk for medication overuse headache, including those that are frequent (eg, ≥4 headaches/month) or long-lasting (eg, ≥12 hours), poorly responsive to acute medications, and those that cause significant disability or diminished quality of life. (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent1">The goals of preventive therapy are to reduce the frequency, severity, and duration of headaches, to improve treatment responsiveness of acute attacks, and to improve overall function or reduce the risk of neurologic impairment. (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment approach</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Start low</strong> – Preventive drugs are started at a low dose and the dose is gradually increased until therapeutic benefit develops, the maximum dose is reached, or side effects become intolerable. (See <a class="local">'Principles of preventive therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Allow for adequate trial</strong> – Efficacy for some agents may be first noted by four weeks and can continue to increase for three to six months. (See <a class="local">'Principles of preventive therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patient education</strong> – We address patient expectations and discuss expected benefits of therapy and how long it will take to achieve them. Important points include (see <a class="local">'Principles of preventive therapy'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Practice good sleep hygiene, set routine meal schedules, participate in regular aerobic exercise, and manage migraine triggers.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Avoid overuse of acute headache therapies (eg, analgesics, triptans, ergots). (See  <a class="medical medical_basics" href="/z/d/html/112403.html" rel="external">"Patient education: Migraines in adults (The Basics)"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Avoid opioids and barbiturates, which can contribute to development of chronic daily headache and may interfere with other preventive therapies. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of medication</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial therapy</strong> – For patients with migraine who have an indication for preventive therapy, we suggest treatment with one of the agents effective in controlled trials rather than other options (<a class="grade" href="https:///uptodate/show/grade_4" rel="external">Grade 2A</a>). These agents include the following (see <a class="local">'Our approach'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">Metoprolol</a> and <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> (see <a class="local">'Beta blockers'</a> above)</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">Amitriptyline</a> and <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a> (see <a class="local">'Antidepressants'</a> above)</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">Topiramate</a> (see <a class="local">'Anticonvulsants'</a> above)</p><p></p><p class="bulletIndent2">The choice among preventive agents should be individualized according to patient-specific characteristics, comorbid conditions, medication side effect profile, medication cost, and patient values and preferences  (<a class="graphic graphic_table graphicRef141580" href="/z/d/graphic/141580.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Inadequate response</strong> – For patients who fail to improve despite an adequate trial of initial pharmacologic therapy, we suggest switching to a migraine prevention medication from a different class (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Treatment failure'</a> above.) </p><p></p><p class="bulletIndent2">Alternative agents that may be effective and are generally well tolerated include the calcium channel blockers <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a> and <a class="drug drug_general" data-topicid="8869" href="/z/d/drug information/8869.html" rel="external">flunarizine</a>, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, and calcitonin gene-related peptide (CGRP) antagonists  (<a class="graphic graphic_table graphicRef141581" href="/z/d/graphic/141581.html" rel="external">table 2</a>). (See <a class="local">'Calcium channel blockers'</a> above and <a class="local">'ACE inhibitors/ARBs'</a> above and <a class="local">'Gabapentin'</a> above and <a class="local">'CGRP antagonists'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonpharmacologic options</strong> – Nonpharmacologic measures that may be beneficial for migraine headache prevention include aerobic exercise, biofeedback, cognitive-behavioral therapies, acupuncture, and neuromodulation. (See <a class="local">'Nonpharmacologic interventions'</a> above.)</p><p></p><p class="headingAnchor" id="H1160928488"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Ashraf Sabahat, MD, Zahid H Bajwa, MD, and Jonathan H Smith, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55:754.</a></li><li><a class="nounderline abstract_t">Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78:1337.</a></li><li><a class="nounderline abstract_t">Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol 2009; 16:968.</a></li><li><a class="nounderline abstract_t">Pringsheim T, Davenport W, Mackie G, et al. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci 2012; 39:S1.</a></li><li><a class="nounderline abstract_t">MacGregor EA. In the clinic. Migraine. Ann Intern Med 2013; 159:ITC5.</a></li><li><a class="nounderline abstract_t">American Headache Society. The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache 2019; 59:1.</a></li><li><a class="nounderline abstract_t">Loder E, Biondi D. General principles of migraine management: the changing role of prevention. Headache 2005; 45 Suppl 1:S33.</a></li><li><a class="nounderline abstract_t">Goadsby PJ, Lipton RB, Ferrari MD. Migraine--current understanding and treatment. N Engl J Med 2002; 346:257.</a></li><li><a class="nounderline abstract_t">Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 2002; 22:491.</a></li><li><a class="nounderline abstract_t">Buse DC, Manack A, Serrano D, et al. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry 2010; 81:428.</a></li><li><a class="nounderline abstract_t">Pringsheim T, Davenport WJ, Becker WJ. Prophylaxis of migraine headache. CMAJ 2010; 182:E269.</a></li><li><a class="nounderline abstract_t">Loder EW, Burch RC. Who Should Try New Antibody Treatments for Migraine? JAMA Neurol 2018; 75:1039.</a></li><li><a class="nounderline abstract_t">Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 2018; 392:2280.</a></li><li><a class="nounderline abstract_t">Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 2019; 394:1030.</a></li><li><a class="nounderline abstract_t">Goadsby PJ, Paemeleire K, Broessner G, et al. Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia 2019; 39:817.</a></li><li><a class="nounderline abstract_t">Kuruppu DK, Tobin J, Dong Y, et al. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments. BMC Neurol 2021; 21:175.</a></li><li><a class="nounderline abstract_t">Ruff DD, Ford JH, Tockhorn-Heidenreich A, et al. Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials. Eur J Neurol 2020; 27:609.</a></li><li><a class="nounderline abstract_t">Shamliyan TA, Choi JY, Ramakrishnan R, et al. Preventive pharmacologic treatments for episodic migraine in adults. J Gen Intern Med 2013; 28:1225.</a></li><li><a class="nounderline abstract_t">Tronvik E, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 2003; 289:65.</a></li><li><a class="nounderline abstract_t">Stovner LJ, Linde M, Gravdahl GB, et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia 2014; 34:523.</a></li><li><a class="nounderline abstract_t">Law M, Morris JK, Jordan R, Wald N. Headaches and the treatment of blood pressure: results from a meta-analysis of 94 randomized placebo-controlled trials with 24,000 participants. Circulation 2005; 112:2301.</a></li><li><a class="nounderline abstract_t">Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev 2004; :CD003225.</a></li><li><a class="nounderline abstract_t">Limmroth V, Michel MC. The prevention of migraine: a critical review with special emphasis on beta-adrenoceptor blockers. Br J Clin Pharmacol 2001; 52:237.</a></li><li><a class="nounderline abstract_t">Rosen JA. Observations on the efficacy of propranolol for the prophylaxis of migraine. Ann Neurol 1983; 13:92.</a></li><li><a class="nounderline abstract_t">Solomon GD, Steel JG, Spaccavento LJ. Verapamil prophylaxis of migraine. A double-blind, placebo-controlled study. JAMA 1983; 250:2500.</a></li><li><a class="nounderline abstract_t">Markley HG, Cheronis JC, Piepho RW. Verapamil in prophylactic therapy of migraine. Neurology 1984; 34:973.</a></li><li><a class="nounderline abstract_t">Jónsdóttir M, Meyer JS, Rogers RL. Efficacy, side effects and tolerance compared during headache treatment with three different calcium blockers. Headache 1987; 27:364.</a></li><li><a class="nounderline abstract_t">Schrader H, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 2001; 322:19.</a></li><li><a class="nounderline abstract_t">Chronicle E, Mulleners W. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev 2004; :CD003226.</a></li><li><a class="nounderline abstract_t">Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004; 291:965.</a></li><li><a class="nounderline abstract_t">Silberstein SD, Neto W, Schmitt J, et al. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004; 61:490.</a></li><li><a class="nounderline abstract_t">Diener HC, Agosti R, Allais G, et al. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2007; 6:1054.</a></li><li><a class="nounderline abstract_t">Linde M, Mulleners WM, Chronicle EP, McCrory DC. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013; :CD010610.</a></li><li><a class="nounderline abstract_t">Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013; :CD010611.</a></li><li class="breakAll">FDA Drug Safety Communication: Valproate anti-seizure products contraindicated for migraine prevention in pregnant women due to decreased IQ scores in exposed children. www.fda.gov/Drugs/DrugSafety/ucm350684.htm (Accessed on May 15, 2013).</li><li><a class="nounderline abstract_t">Linde M, Mulleners WM, Chronicle EP, McCrory DC. Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013; :CD010609.</a></li><li><a class="nounderline abstract_t">Silberstein S, Goode-Sellers S, Twomey C, et al. Randomized, double-blind, placebo-controlled, phase II trial of gabapentin enacarbil for migraine prophylaxis. Cephalalgia 2013; 33:101.</a></li><li><a class="nounderline abstract_t">Goadsby PJ, Dodick DW, Ailani J, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. Lancet Neurol 2020; 19:727.</a></li><li class="breakAll">FDA approves novel preventive treatment for migraine. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm608120.htm (Accessed on May 18, 2018).</li><li class="breakAll">FDA Approved Drug Products. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=761089#collapseLables (Accessed on September 17, 2018).</li><li class="breakAll">FDA Approved Drug Products. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=761063 (Accessed on October 09, 2018).</li><li class="breakAll">FDA Approved Drug Products. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761119Orig1s000TOC.cfm (Accessed on May 30, 2020).</li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212728s006lbl.pdf.</li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215206Orig1s000lbl.pdf (Accessed on October 01, 2021).</li><li><a class="nounderline abstract_t">Goadsby PJ, Reuter U, Hallström Y, et al. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med 2017; 377:2123.</a></li><li><a class="nounderline abstract_t">Goadsby PJ, Reuter U, Lanteri-Minet M, et al. Long-term Efficacy and Safety of Erenumab: Results From 64 Weeks of the LIBERTY Study. Neurology 2021; 96:e2724.</a></li><li><a class="nounderline abstract_t">Ashina M, Goadsby PJ, Dodick DW, et al. Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials. JAMA Neurol 2022; 79:159.</a></li><li><a class="nounderline abstract_t">Martin AW, Cubellis M. Evaluation of the change in efficacy of erenumab when used long-term for migraine prevention after initial established benefit in a veteran population. Pharmacotherapy 2023; 43:494.</a></li><li class="breakAll">Aimovig (erenumab-aooe) injection, for subcutaneous use, prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761077s007lbl.pdf (Accessed on June 03, 2020).</li><li><a class="nounderline abstract_t">In Brief: Hypertension with Erenumab (Aimovig). Med Lett Drugs Ther 2021; 63:56.</a></li><li><a class="nounderline abstract_t">Dodick DW, Silberstein SD, Bigal ME, et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA 2018; 319:1999.</a></li><li><a class="nounderline abstract_t">Goadsby PJ, Silberstein SD, Yeung PP, et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study. Neurology 2020; 95:e2487.</a></li><li><a class="nounderline abstract_t">Skljarevski V, Oakes TM, Zhang Q, et al. Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial. JAMA Neurol 2018; 75:187.</a></li><li><a class="nounderline abstract_t">Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia 2018; 38:1442.</a></li><li><a class="nounderline abstract_t">Mulleners WM, Kim BK, Láinez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 2020; 19:814.</a></li><li><a class="nounderline abstract_t">Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial. JAMA Neurol 2018; 75:1080.</a></li><li><a class="nounderline abstract_t">Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 2020; 40:241.</a></li><li><a class="nounderline abstract_t">Ashina M, Lanteri-Minet M, Pozo-Rosich P, et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 2022; 21:597.</a></li><li><a class="nounderline abstract_t">Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 2020; 94:e1365.</a></li><li><a class="nounderline abstract_t">Winner PK, McAllister P, Chakhava G, et al. Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial. JAMA 2021; 325:2348.</a></li><li class="breakAll">Vyepti (eptinezumab-jjmr) injection, for intravenous use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761119s000lbl.pdf (Accessed on March 19, 2020).</li><li><a class="nounderline abstract_t">Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet 2021; 397:51.</a></li><li><a class="nounderline abstract_t">Ailani J, Lipton RB, Goadsby PJ, et al. Atogepant for the Preventive Treatment of Migraine. N Engl J Med 2021; 385:695.</a></li><li><a class="nounderline abstract_t">Klein BC, Miceli R, Severt L, et al. Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial. Cephalalgia 2023; 43:3331024221128250.</a></li><li><a class="nounderline abstract_t">Sun W, Cheng H, Xia B, et al. Comparative Efficacy and Safety of Five Anti-calcitonin Gene-related Peptide Agents for Migraine Prevention: A Network Meta-analysis. Clin J Pain 2023; 39:560.</a></li><li><a class="nounderline abstract_t">MaassenVanDenBrink A, Meijer J, Villalón CM, Ferrari MD. Wiping Out CGRP: Potential Cardiovascular Risks. Trends Pharmacol Sci 2016; 37:779.</a></li><li><a class="nounderline abstract_t">Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med 2017; 377:2113.</a></li><li><a class="nounderline abstract_t">Ashina M, Dodick D, Goadsby PJ, et al. Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study. Neurology 2017; 89:1237.</a></li><li><a class="nounderline abstract_t">Loder EW, Robbins MS. Monoclonal Antibodies for Migraine Prevention: Progress, but Not a Panacea. JAMA 2018; 319:1985.</a></li><li><a class="nounderline abstract_t">Kudrow D, Pascual J, Winner PK, et al. Vascular safety of erenumab for migraine prevention. Neurology 2020; 94:e497.</a></li><li><a class="nounderline abstract_t">Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet 2019; 394:1765.</a></li><li><a class="nounderline abstract_t">Diener HC, McAllister P, Jürgens TP, et al. Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies. Cephalalgia 2022; 42:769.</a></li><li class="breakAll">Eptinezumab prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761119s002lbl.pdf (Accessed on September 30, 2021).</li><li class="breakAll">Femanezumab prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761089s013lbl.pdf (Accessed on September 30, 2021).</li><li><a class="nounderline abstract_t">von Luckner A, Riederer F. Magnesium in Migraine Prophylaxis-Is There an Evidence-Based Rationale? A Systematic Review. Headache 2018; 58:199.</a></li><li><a class="nounderline abstract_t">Sazali S, Badrin S, Norhayati MN, Idris NS. Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine-a meta-analysis. BMJ Open 2021; 11:e039358.</a></li><li><a class="nounderline abstract_t">Herd CP, Tomlinson CL, Rick C, et al. Botulinum toxins for the prevention of migraine in adults. Cochrane Database Syst Rev 2018; 6:CD011616.</a></li><li><a class="nounderline abstract_t">Chen YS, Lee HF, Tsai CH, et al. Effect of Vitamin B2 supplementation on migraine prophylaxis: a systematic review and meta-analysis. Nutr Neurosci 2022; 25:1801.</a></li><li><a class="nounderline abstract_t">Leite Pacheco R, de Oliveira Cruz Latorraca C, Adriano Leal Freitas da Costa A, et al. Melatonin for preventing primary headache: A systematic review. Int J Clin Pract 2018; 72:e13203.</a></li><li><a class="nounderline abstract_t">Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 2000; 40:445.</a></li><li><a class="nounderline abstract_t">Evers S, Vollmer-Haase J, Schwaag S, et al. Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study. Cephalalgia 2004; 24:838.</a></li><li><a class="nounderline abstract_t">Elkind AH, O'Carroll P, Blumenfeld A, et al. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain 2006; 7:688.</a></li><li><a class="nounderline abstract_t">Naumann M, So Y, Argoff CE, et al. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70:1707.</a></li><li><a class="nounderline abstract_t">Tepper SJ, Rapoport A, Sheftell F. The pathophysiology of migraine. Neurologist 2001; 7:279.</a></li><li><a class="nounderline abstract_t">Markley HG. CoEnzyme Q10 and riboflavin: the mitochondrial connection. Headache 2012; 52 Suppl 2:81.</a></li><li><a class="nounderline abstract_t">Sándor PS, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 2005; 64:713.</a></li><li><a class="nounderline abstract_t">Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998; 50:466.</a></li><li><a class="nounderline abstract_t">Wider B, Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev 2015; 4:CD002286.</a></li><li><a class="nounderline abstract_t">Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J (Clin Res Ed) 1985; 291:569.</a></li><li><a class="nounderline abstract_t">Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988; 2:189.</a></li><li><a class="nounderline abstract_t">Palevitch D, Earon G, Carasso R. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. Phytotherapy Research 1997; 11:508.</a></li><li><a class="nounderline abstract_t">Diener HC, Pfaffenrath V, Schnitker J, et al. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention--a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia 2005; 25:1031.</a></li><li><a class="nounderline abstract_t">De Weerdt CJ, Bootsma HP, Hendriks H. Herbal medicines in migraine prevention Randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomedicine 1996; 3:225.</a></li><li><a class="nounderline abstract_t">Pfaffenrath V, Diener HC, Fischer M, et al. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia 2002; 22:523.</a></li><li><a class="nounderline abstract_t">Teigen L, Boes CJ. An evidence-based review of oral magnesium supplementation in the preventive treatment of migraine. Cephalalgia 2015; 35:912.</a></li><li><a class="nounderline abstract_t">Facchinetti F, Sances G, Borella P, et al. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache 1991; 31:298.</a></li><li><a class="nounderline abstract_t">Peikert A, Wilimzig C, Köhne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996; 16:257.</a></li><li><a class="nounderline abstract_t">Köseoglu E, Talaslioglu A, Gönül AS, Kula M. The effects of magnesium prophylaxis in migraine without aura. Magnes Res 2008; 21:101.</a></li><li><a class="nounderline abstract_t">Pfaffenrath V, Wessely P, Meyer C, et al. Magnesium in the prophylaxis of migraine--a double-blind placebo-controlled study. Cephalalgia 1996; 16:436.</a></li><li><a class="nounderline abstract_t">Alstadhaug KB, Odeh F, Salvesen R, Bekkelund SI. Prophylaxis of migraine with melatonin: a randomized controlled trial. Neurology 2010; 75:1527.</a></li><li><a class="nounderline abstract_t">Gonçalves AL, Martini Ferreira A, Ribeiro RT, et al. Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. J Neurol Neurosurg Psychiatry 2016; 87:1127.</a></li><li><a class="nounderline abstract_t">Lindegaard KF, Ovrelid L, Sjaastad O. Naproxen in the prevention of migraine attacks. A double-blind placebo-controlled cross-over study. Headache 1980; 20:96.</a></li><li><a class="nounderline abstract_t">Ziegler DK, Ellis DJ. Naproxen in prophylaxis of migraine. Arch Neurol 1985; 42:582.</a></li><li><a class="nounderline abstract_t">Welch KM, Ellis DJ, Keenan PA. Successful migraine prophylaxis with naproxen sodium. Neurology 1985; 35:1304.</a></li><li><a class="nounderline abstract_t">Sargent J, Solbach P, Damasio H, et al. A comparison of naproxen sodium to propranolol hydrochloride and a placebo control for the prophylaxis of migraine headache. Headache 1985; 25:320.</a></li><li><a class="nounderline abstract_t">Sances G, Martignoni E, Fioroni L, et al. Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. Headache 1990; 30:705.</a></li><li class="breakAll">Gray RN, Goslin RE, McCrory DC, et al. Drug treatments for the prevention of migraine headache. Rockville (MD): Agency for Health Care Policy and Research (US); 1999. http://www.ncbi.nlm.nih.gov/books/NBK45457/ (Accessed on April 30, 2012).</li><li><a class="nounderline abstract_t">Stensrud P, Sjaastad O. Clinical trial of a new anti-bradykinin, anti-inflammatory drug, ketoprofen (19.583 r.p.) in migraine prophylaxis. Headache 1974; 14:96.</a></li><li><a class="nounderline abstract_t">Buettner C, Nir RR, Bertisch SM, et al. Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial. Ann Neurol 2015; 78:970.</a></li><li class="breakAll">Bravo TP, Vargas BB. Migraine preventative butterbur has safety concerns. Neurology Times. http://www.neurologytimes.com/headache-and-migraine/migraine-preventative-butterbur-has-safety-concerns (Accessed on August 10, 2015).</li><li><a class="nounderline abstract_t">Grossmann M, Schmidramsl H. An extract of Petasites hybridus is effective in the prophylaxis of migraine. Int J Clin Pharmacol Ther 2000; 38:430.</a></li><li><a class="nounderline abstract_t">Diener HC, Rahlfs VW, Danesch U. The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. Eur Neurol 2004; 51:89.</a></li><li><a class="nounderline abstract_t">Lipton RB, Göbel H, Einhäupl KM, et al. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 2004; 63:2240.</a></li><li><a class="nounderline abstract_t">Mauskop A. Nonmedication, alternative, and complementary treatments for migraine. Continuum (Minneap Minn) 2012; 18:796.</a></li><li><a class="nounderline abstract_t">Varkey E, Cider A, Carlsson J, Linde M. Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia 2011; 31:1428.</a></li><li><a class="nounderline abstract_t">Ahn AH. Why does increased exercise decrease migraine? Curr Pain Headache Rep 2013; 17:379.</a></li><li><a class="nounderline abstract_t">Holroyd KA, Cottrell CK, O'Donnell FJ, et al. Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. BMJ 2010; 341:c4871.</a></li><li><a class="nounderline abstract_t">Martin PR. Behavioral management of migraine headache triggers: learning to cope with triggers. Curr Pain Headache Rep 2010; 14:221.</a></li><li><a class="nounderline abstract_t">Varangot-Reille C, Suso-Martí L, Romero-Palau M, et al. Effects of Different Therapeutic Exercise Modalities on Migraine or Tension-Type Headache: A Systematic Review and Meta-Analysis with a Replicability Analysis. J Pain 2022; 23:1099.</a></li><li><a class="nounderline abstract_t">Meissner K, Fässler M, Rücker G, et al. Differential effectiveness of placebo treatments: a systematic review of migraine prophylaxis. JAMA Intern Med 2013; 173:1941.</a></li><li><a class="nounderline abstract_t">Linde K, Allais G, Brinkhaus B, et al. Acupuncture for the prevention of episodic migraine. Cochrane Database Syst Rev 2016; :CD001218.</a></li><li><a class="nounderline abstract_t">Zhao L, Chen J, Li Y, et al. The Long-term Effect of Acupuncture for Migraine Prophylaxis: A Randomized Clinical Trial. JAMA Intern Med 2017; 177:508.</a></li><li><a class="nounderline abstract_t">Xu J, Zhang FQ, Pei J, Ji J. Acupuncture for migraine without aura: a systematic review and meta-analysis. J Integr Med 2018; 16:312.</a></li><li><a class="nounderline abstract_t">Li Y, Zheng H, Witt CM, et al. Acupuncture for migraine prophylaxis: a randomized controlled trial. CMAJ 2012; 184:401.</a></li><li><a class="nounderline abstract_t">Linde K, Streng A, Jürgens S, et al. Acupuncture for patients with migraine: a randomized controlled trial. JAMA 2005; 293:2118.</a></li><li><a class="nounderline abstract_t">Diener HC, Kronfeld K, Boewing G, et al. Efficacy of acupuncture for the prophylaxis of migraine: a multicentre randomised controlled clinical trial. Lancet Neurol 2006; 5:310.</a></li><li><a class="nounderline abstract_t">Kaptchuk TJ. Placebo studies and ritual theory: a comparative analysis of Navajo, acupuncture and biomedical healing. Philos Trans R Soc Lond B Biol Sci 2011; 366:1849.</a></li><li><a class="nounderline abstract_t">Kerr CE, Shaw JR, Conboy LA, et al. Placebo acupuncture as a form of ritual touch healing: a neurophenomenological model. Conscious Cogn 2011; 20:784.</a></li><li><a class="nounderline abstract_t">Schoenen J, Vandersmissen B, Jeangette S, et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology 2013; 80:697.</a></li><li><a class="nounderline abstract_t">Starling AJ, Tepper SJ, Marmura MJ, et al. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia 2018; 38:1038.</a></li><li><a class="nounderline abstract_t">Mohamad Safiai NI, Mohamad NA, Basri H, et al. High-frequency repetitive transcranial magnetic stimulation at dorsolateral prefrontal cortex for migraine prevention: A systematic review and meta-analysis. Cephalalgia 2022; 42:1071.</a></li><li><a class="nounderline abstract_t">Kinfe TM, Pintea B, Muhammad S, et al. Cervical non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: a prospective observational cohort study. J Headache Pain 2015; 16:101.</a></li><li><a class="nounderline abstract_t">Grazzi L, Egeo G, Calhoun AH, et al. Non-invasive Vagus Nerve Stimulation (nVNS) as mini-prophylaxis for menstrual/menstrually related migraine: an open-label study. J Headache Pain 2016; 17:91.</a></li><li><a class="nounderline abstract_t">Diener HC, Goadsby PJ, Ashina M, et al. Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial. Cephalalgia 2019; 39:1475.</a></li><li><a class="nounderline abstract_t">Martin PR. Managing headache triggers: think 'coping' not 'avoidance'. Cephalalgia 2010; 30:634.</a></li><li><a class="nounderline abstract_t">Martin PR, Reece J, Callan M, et al. Behavioral management of the triggers of recurrent headache: a randomized controlled trial. Behav Res Ther 2014; 61:1.</a></li><li><a class="nounderline abstract_t">Guyuron B, Reed D, Kriegler JS, et al. A placebo-controlled surgical trial of the treatment of migraine headaches. Plast Reconstr Surg 2009; 124:461.</a></li><li><a class="nounderline abstract_t">Mathew PG. A critical evaluation of migraine trigger site deactivation surgery. Headache 2014; 54:142.</a></li><li><a class="nounderline abstract_t">Diener HC, Bingel U. Surgical treatment for migraine: Time to fight against the knife. Cephalalgia 2015; 35:465.</a></li><li><a class="nounderline abstract_t">Dowson A, Mullen MJ, Peatfield R, et al. Migraine Intervention With STARFlex Technology (MIST) trial: a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation 2008; 117:1397.</a></li><li><a class="nounderline abstract_t">Mattle HP, Evers S, Hildick-Smith D, et al. Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial. Eur Heart J 2016; 37:2029.</a></li><li><a class="nounderline abstract_t">Schwedt TJ, Demaerschalk BM, Dodick DW. Patent foramen ovale and migraine: a quantitative systematic review. Cephalalgia 2008; 28:531.</a></li><li><a class="nounderline abstract_t">Wilmshurst PT, Nightingale S, Walsh KP, Morrison WL. Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons. Lancet 2000; 356:1648.</a></li><li><a class="nounderline abstract_t">Schwerzmann M, Wiher S, Nedeltchev K, et al. Percutaneous closure of patent foramen ovale reduces the frequency of migraine attacks. Neurology 2004; 62:1399.</a></li><li><a class="nounderline abstract_t">Post MC, Thijs V, Herroelen L, Budts WI. Closure of a patent foramen ovale is associated with a decrease in prevalence of migraine. Neurology 2004; 62:1439.</a></li><li><a class="nounderline abstract_t">Reisman M, Christofferson RD, Jesurum J, et al. Migraine headache relief after transcatheter closure of patent foramen ovale. J Am Coll Cardiol 2005; 45:493.</a></li><li><a class="nounderline abstract_t">Azarbal B, Tobis J, Suh W, et al. Association of interatrial shunts and migraine headaches: impact of transcatheter closure. J Am Coll Cardiol 2005; 45:489.</a></li><li><a class="nounderline abstract_t">Giardini A, Donti A, Formigari R, et al. Transcatheter patent foramen ovale closure mitigates aura migraine headaches abolishing spontaneous right-to-left shunting. Am Heart J 2006; 151:922.e1.</a></li><li><a class="nounderline abstract_t">Anzola GP, Frisoni GB, Morandi E, et al. Shunt-associated migraine responds favorably to atrial septal repair: a case-control study. Stroke 2006; 37:430.</a></li><li><a class="nounderline abstract_t">Mortelmans K, Post M, Thijs V, et al. The influence of percutaneous atrial septal defect closure on the occurrence of migraine. Eur Heart J 2005; 26:1533.</a></li><li><a class="nounderline abstract_t">Yankovsky AE, Kuritzky A. Transformation into daily migraine with aura following transcutaneous atrial septal defect closure. Headache 2003; 43:496.</a></li><li><a class="nounderline abstract_t">Rodés-Cabau J, Molina C, Serrano-Munuera C, et al. Migraine with aura related to the percutaneous closure of an atrial septal defect. Catheter Cardiovasc Interv 2003; 60:540.</a></li></ol></div><div id="topicVersionRevision">Topic 3345 Version 93.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10993991" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22529202" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19708964" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22683887" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Canadian Headache Society guideline for migraine prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24189604" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : In the clinic. Migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30536394" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15833089" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : General principles of migraine management: the changing role of prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11807151" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Migraine--current understanding and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12230591" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Migraine: preventive treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20164501" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20159899" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prophylaxis of migraine headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29799961" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Who Should Try New Antibody Treatments for Migraine?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30360965" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31427046" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30982348" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33892641" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31692188" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23592242" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Preventive pharmacologic treatments for episodic migraine in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12503978" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24335848" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16216977" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Headaches and the treatment of blood pressure: results from a meta-analysis of 94 randomized placebo-controlled trials with 24,000 participants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15106196" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Propranolol for migraine prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11560555" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The prevention of migraine: a critical review with special emphasis on beta-adrenoceptor blockers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6338806" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Observations on the efficacy of propranolol for the prophylaxis of migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6355533" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Verapamil prophylaxis of migraine. A double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6539877" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Verapamil in prophylactic therapy of migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3654196" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Efficacy, side effects and tolerance compared during headache treatment with three different calcium blockers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11141144" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15266476" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Anticonvulsant drugs for migraine prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14982912" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Topiramate for migraine prevention: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15096395" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Topiramate in migraine prevention: results of a large controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17988947" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23797676" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Topiramate for the prophylaxis of episodic migraine in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23797677" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23797677" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23797675" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23165696" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Randomized, double-blind, placebo-controlled, phase II trial of gabapentin enacarbil for migraine prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32822633" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32822633" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32822633" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32822633" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32822633" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32822633" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32822633" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29171821" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A Controlled Trial of Erenumab for Episodic Migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33910942" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Long-term Efficacy and Safety of Erenumab: Results From 64 Weeks of the LIBERTY Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34928306" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37158755" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Evaluation of the change in efficacy of erenumab when used long-term for migraine prevention after initial established benefit in a veteran population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37158755" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Evaluation of the change in efficacy of erenumab when used long-term for migraine prevention after initial established benefit in a veteran population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : In Brief: Hypertension with Erenumab (Aimovig)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29800211" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32913018" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29255900" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29848108" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32949542" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29813147" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32075406" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35716692" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32209650" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34128999" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34128999" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33338437" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34407343" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Atogepant for the Preventive Treatment of Migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36620892" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37278480" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Comparative Efficacy and Safety of Five Anti-calcitonin Gene-related Peptide Agents for Migraine Prevention: A Network Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27338837" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Wiping Out CGRP: Potential Cardiovascular Risks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29171818" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Fremanezumab for the Preventive Treatment of Chronic Migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28835404" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29800193" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Monoclonal Antibodies for Migraine Prevention: Progress, but Not a Panacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31852816" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Vascular safety of erenumab for migraine prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31668411" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Targeting calcitonin gene-related peptide: a new era in migraine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35331009" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35331009" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35331009" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29131326" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Magnesium in Migraine Prophylaxis-Is There an Evidence-Based Rationale? A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33402403" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine-a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29939406" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Botulinum toxins for the prevention of migraine in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33779525" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Effect of Vitamin B2 supplementation on migraine prophylaxis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29799148" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Melatonin for preventing primary headache: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10849039" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15377314" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17018329" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18458231" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12803669" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The pathophysiology of migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23030537" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : CoEnzyme Q10 and riboflavin: the mitochondrial connection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728298" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9484373" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25892430" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Feverfew for preventing migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3929876" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Efficacy of feverfew as prophylactic treatment of migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2899663" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Randomised double-blind placebo-controlled trial of feverfew in migraine prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16232154" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention--a randomized, double-blind, multicentre, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23195074" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Herbal medicines in migraine prevention Randomized double-blind placebo-controlled crossover trial of a feverfew preparation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12230594" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25533715" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : An evidence-based review of oral magnesium supplementation in the preventive treatment of migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1860787" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8792038" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18705538" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : The effects of magnesium prophylaxis in migraine without aura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8902254" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Magnesium in the prophylaxis of migraine--a double-blind placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20975054" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Prophylaxis of migraine with melatonin: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27165014" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6989789" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Naproxen in the prevention of migraine attacks. A double-blind placebo-controlled cross-over study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4004602" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Naproxen in prophylaxis of migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4022376" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Successful migraine prophylaxis with naproxen sodium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3902723" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : A comparison of naproxen sodium to propranolol hydrochloride and a placebo control for the prophylaxis of migraine headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2074162" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2074162" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4604234" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Clinical trial of a new anti-bradykinin, anti-inflammatory drug, ketoprofen (19.583 r.p.) in migraine prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26418341" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26418341" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11020030" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : An extract of Petasites hybridus is effective in the prophylaxis of migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14752215" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15623680" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Petasites hybridus root (butterbur) is an effective preventive treatment for migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22868542" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Nonmedication, alternative, and complementary treatments for migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21890526" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24190863" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Why does increased exercise decrease migraine?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20880898" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20425190" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Behavioral management of migraine headache triggers: learning to cope with triggers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34929374" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Effects of Different Therapeutic Exercise Modalities on Migraine or Tension-Type Headache: A Systematic Review and Meta-Analysis with a Replicability Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24126676" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Differential effectiveness of placebo treatments: a systematic review of migraine prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27351677" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Acupuncture for the prevention of episodic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28241154" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : The Long-term Effect of Acupuncture for Migraine Prophylaxis: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30007828" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Acupuncture for migraine without aura: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22231691" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Acupuncture for migraine prophylaxis: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15870415" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Acupuncture for patients with migraine: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16545747" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Efficacy of acupuncture for the prophylaxis of migraine: a multicentre randomised controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21576142" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Placebo studies and ritual theory: a comparative analysis of Navajo, acupuncture and biomedical healing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21397519" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Placebo acupuncture as a form of ritual touch healing: a neurophenomenological model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23390177" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29504483" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35435045" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : High-frequency repetitive transcranial magnetic stimulation at dorsolateral prefrontal cortex for migraine prevention: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26631234" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Cervical non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: a prospective observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27699586" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Non-invasive Vagus Nerve Stimulation (nVNS) as mini-prophylaxis for menstrual/menstrually related migraine: an open-label study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31522546" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19673895" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Managing headache triggers: think 'coping' not 'avoidance'.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25108482" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Behavioral management of the triggers of recurrent headache: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19644260" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : A placebo-controlled surgical trial of the treatment of migraine headaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24116941" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : A critical evaluation of migraine trigger site deactivation surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25143552" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Surgical treatment for migraine: Time to fight against the knife.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18316488" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Migraine Intervention With STARFlex Technology (MIST) trial: a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26908949" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18355348" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Patent foramen ovale and migraine: a quantitative systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11089825" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15111681" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Percutaneous closure of patent foramen ovale reduces the frequency of migraine attacks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15111695" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Closure of a patent foramen ovale is associated with a decrease in prevalence of migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15708692" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Migraine headache relief after transcatheter closure of patent foramen ovale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15708691" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Association of interatrial shunts and migraine headaches: impact of transcatheter closure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16569564" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Transcatheter patent foramen ovale closure mitigates aura migraine headaches abolishing spontaneous right-to-left shunting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16373630" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Shunt-associated migraine responds favorably to atrial septal repair: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15746154" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : The influence of percutaneous atrial septal defect closure on the occurrence of migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12752756" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Transformation into daily migraine with aura following transcutaneous atrial septal defect closure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14624438" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Migraine with aura related to the percutaneous closure of an atrial septal defect.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
